Chemomab Therapeutics Ltd. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים CMMB

The historical year-over-year EPS growth (TTM) demonstrates profit dynamics, where the final value of the parameter equals 57.40. The current trend complements the development of unique antibodies to combat tissue fibrosis. The scientific potential of Chemomab Therapeutics (CMMB) is supported by a staff of specialized biologists and an RSU system, although the lack of sales leads to the depletion of reserves to fund clinical trials.
Chemomab Therapeutics Ltd. - פילוחים אנליטיים ומדדי מפתח (CMMB)

Year-over-year (TTM) EPS growth reflects the rate of change in net income per share over a rolling twelve-month period, allowing for an assessment of capital generation efficiency relative to historical performance. By analyzing the YoY TTM earnings per share dynamics, an investor can see the impact of CM-101 clinical successes and FDA orphan designations on the fundamental value of Chemomab Therapeutics (CMMB) and its M&A attractiveness.